The is an observational, prospective study to evaluate the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated chronic total occlusion (CTO) percutaneous coronary intervention (PCI)
The DyeVert System is a disposable, FDA-approved device that interfaces with standard manifold systems to reduce the amount of contrast used in catheterization procedures, while maintaining fluoroscopic image opacity. No study has assessed use of the system in CTO PCI. It would be expected that savings in CTO procedures may be less than non-CTO procedures due to catheter sizing and number of open guide injections required. Open guide injections through larger catheters do not provide for the as much resistance, therefore decreasing the need for contrast to be diverted
Study Type
OBSERVATIONAL
Enrollment
21
The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
Abbott Northwestern Hospital
Minneapolis, Minnesota, United States
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States
Minneapolis Heart Institute
Minneapolis, Minnesota, United States
Contrast volume administration during CTO PCI
The hypothesis of the study is that use of the DyeVert System will result in lower contrast volume, determined through real-time monitoring with the DyeVert System.
Time frame: During the CTO PCI procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.